NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free SYRS Stock Alerts $5.35 -0.49 (-8.39%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.15▼$5.9050-Day Range$5.35▼$7.7552-Week Range$2.09▼$8.17Volume318,061 shsAverage Volume187,515 shsMarket Capitalization$112.72 millionP/E RatioN/ADividend YieldN/APrice Target$12.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Syros Pharmaceuticals alerts: Email Address Syros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.5% Upside$12.33 Price TargetShort InterestBearish9.57% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.66Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.75) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.21 out of 5 starsMedical Sector184th out of 939 stocksPharmaceutical Preparations Industry77th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.33, Syros Pharmaceuticals has a forecasted upside of 130.5% from its current price of $5.35.Amount of Analyst CoverageSyros Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.57% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Syros Pharmaceuticals has recently increased by 31.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 64.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.88. Previous Next 2.0 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($3.75) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Syros Pharmaceuticals Stock (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold at StockNews.comMarch 29, 2024 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) to Post FY2028 Earnings of $11.61 Per Share, Brookline Capital Management ForecastsMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 28, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene TrialsMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 27, 2024 | markets.businessinsider.comSyros Pharmaceuticals earnings preview: what Wall Street is expectingMarch 27, 2024 | investorplace.comSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial DevelopmentsMarch 27, 2024 | businesswire.comSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateMarch 25, 2024 | finance.yahoo.comSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialMarch 25, 2024 | americanbankingnews.comSyros Pharmaceuticals (SYRS) Scheduled to Post Quarterly Earnings on WednesdayMarch 20, 2024 | businesswire.comSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024March 16, 2024 | finance.yahoo.comSYRS Apr 2024 10.000 callMarch 11, 2024 | msn.comFibroGen appoints Deyaa Adib as Chief Medical OfficerFebruary 28, 2024 | finance.yahoo.comSYRS Jul 2024 2.500 callFebruary 27, 2024 | finance.yahoo.comInvestors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past yearFebruary 27, 2024 | finance.yahoo.comSyros to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | businesswire.comSyros to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 23, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS)February 17, 2024 | finance.yahoo.comSYRS Mar 2024 7.500 putJanuary 23, 2024 | thestreet.comSyros Pharmaceuticals Inc.January 18, 2024 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great ChoiceJanuary 17, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's WhyJanuary 16, 2024 | finance.yahoo.comWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should KnowJanuary 16, 2024 | finance.yahoo.comWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should KnowSee More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2021Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees117Year FoundedN/APrice Target and Rating Average Stock Price Target$12.33 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+130.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,650,000.00 Net MarginsN/A Pretax Margin-1,193.45% Return on Equity-155.06% Return on Assets-68.52% Debt Debt-to-Equity Ratio1.09 Current Ratio4.31 Quick Ratio4.31 Sales & Book Value Annual Sales$14.88 million Price / Sales7.58 Cash FlowN/A Price / Cash FlowN/A Book Value$6.32 per share Price / Book0.85Miscellaneous Outstanding Shares21,070,000Free Float18,865,000Market Cap$112.72 million OptionableOptionable Beta1.79 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Richard A. Young Ph.D. (Age 70)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $108.37kDr. David A. Roth M.D. (Age 61)Chief Medical Officer Comp: $679.52kMr. Conley Chee (Age 54)CEO, President & Director Dr. James E. Bradner M.D. (Age 52)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Jason Haas (Age 56)Chief Financial Officer Comp: $457.22kMs. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 56)J.D., Chief Legal Officer & Head of Business Development Comp: $127.07kMs. Lisa RobertsVice President of Human ResourcesMs. Kristin Stephens (Age 51)Chief Development Officer More ExecutivesKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMEmergent BioSolutionsNYSE:EBSCitius PharmaceuticalsNASDAQ:CTXRAnnovis BioNYSE:ANVSPDS BiotechnologyNASDAQ:PDSBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 236,620 shares on 3/11/2024Ownership: 3.630%Goldman Sachs Group Inc.Bought 133,149 shares on 3/1/2024Ownership: 1.138%Flagship Pioneering Inc.Bought 300,000 shares on 2/15/2024Ownership: 6.141%Vanguard Group Inc.Bought 236,620 shares on 2/15/2024Ownership: 3.630%Citadel Advisors LLCBought 1,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SYRS Stock Analysis - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 1-year target prices for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $7.00 to $15.00. On average, they anticipate the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 130.5% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2024? Syros Pharmaceuticals' stock was trading at $7.79 at the start of the year. Since then, SYRS shares have decreased by 31.3% and is now trading at $5.35. View the best growth stocks for 2024 here. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,740,000 shares, an increase of 31.8% from the February 29th total of 1,320,000 shares. Based on an average daily volume of 212,500 shares, the days-to-cover ratio is currently 8.2 days. Currently, 9.6% of the shares of the stock are sold short. View Syros Pharmaceuticals' Short Interest. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share for the quarter, topping the consensus estimate of ($4.40) by $0.30. The firm had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative trailing twelve-month return on equity of 184.10%. During the same quarter in the previous year, the company posted ($4.30) earnings per share. When did Syros Pharmaceuticals' stock split? Shares of Syros Pharmaceuticals reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.05%), Avidity Partners Management LP (7.94%), Blue Owl Capital Holdings LP (7.09%), Point72 Asset Management L.P. (6.99%), Flagship Pioneering Inc. (6.14%) and Vanguard Group Inc. (3.63%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.